2026-05-17T00:18:32Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/175642024-09-21T22:09:52Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud author Molina-Vega, MarIa author Muñoz-Garach, Araceli author Damas-Fuentes, Miguel author Fernández-García, José Carlos author Tinahones, Francisco J 2024-02-08T14:40:53Z 2024-02-08T14:40:53Z 2018 10.4103/aja.aja_44_18 1745-7262 Asian journal of andrology http://hdl.handle.net/10668/12679 29974886 http://hdl.handle.net/20.500.12105/17564 Male hypogonadism associated with obesity is a very prevalent condition and is increasing in parallel with the epidemic prevalence of obesity. Low testosterone levels promote higher fat mass with reduced lean mass. Male hypogonadism is related to an increase in associated cardiometabolic complications, such as hypertension, type 2 diabetes mellitus, the metabolic syndrome, and cardiovascular disease. Its influence as a comorbidity of obesity is becoming more evident and should be evaluated and treated in at-risk patients. Mechanisms involved in this relationship include body composition changes, the presence of adipokines, insulin resistance, and other factors, some of which are still unknown. Weight loss and treatment to replace testosterone levels improve the metabolic profile and quality of life in patients with obesity and hypogonadism; these beneficial effects depend on treatment modality and duration of therapy. The use of testosterone replacement therapy may be indicated, as it has not been shown to increase cardiovascular risk, and retrospective studies suggest a reduction in events in men with metabolic syndrome and type 2 diabetes. eng Adipose tissue Male hypogonadism Obesity Testosterone Secondary male hypogonadism: A prevalent but overlooked comorbidity of obesity. research article